Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Gavin Bart. (2012) Maintenance Medication for Opiate Addiction: The Foundation of Recovery. Journal of Addictive Diseases 31:3, pages 207-225.
Read now
Read now
DonnaM. Coviello, JamesW. Cornish, KevinG. Lynch, TamaraY. Boney, CynthiaA. Clark, JoshuaD. Lee, PeterD. Friedmann, EdwardV. Nunes, TimothyW. Kinlock, MichaelS. Gordon, RobertP. Schwartz, ElieS. Nuwayser & CharlesP. O’Brien. (2012) A Multisite Pilot Study of Extended-Release Injectable Naltrexone Treatment for Previously Opioid-Dependent Parolees and Probationers. Substance Abuse 33:1, pages 48-59.
Read now
Read now
Paolo Mannelli, Kathleen S Peindl & Li-Tzy Wu. (2011) Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Substance Abuse and Rehabilitation 2, pages 113-123.
Read now
Read now
Thamizan K Tucker, Alison J Ritter, Claire Maher & Henry Jackson. (2004) Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug and Alcohol Review 23:3, pages 299-309.
Read now
Read now
A. Thomas McLellan. (2002) Is addiction an illness—can it be treated?. Substance Abuse 23:sup1, pages 67-94.
Read now
Read now
James W. Cornish, David Henson, Sanford Levine, Joseph Volpicelli, Charles E. Inturrisi, Byron C. Yoburn & Charles P. O'Brien. (1993) Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers. American Journal on Addictions 2:1, pages 34-38.
Read now
Read now
Robert A. Greenstein, Charles P. O'Brien, A. Thomas McLellan, George E. Woody, John Grabowski, Melody Long, Geraldine Coyle-Perkins & Anita Vittor. (1981) Naltrexone: A Short-Term Treatment for Opiate Dependence. The American Journal of Drug and Alcohol Abuse 8:3, pages 291-300.
Read now
Read now
Arnold Schecter. (1980) The Role of Narcotic Antagonists in the Rehabilitation of Opiate Addicts: A Review of Naltrexone. The American Journal of Drug and Alcohol Abuse 7:1, pages 1-18.
Read now
Read now
David C. Lewis, Joseph Mayer, Ronald G. Hersch & Rebecca Black. (1978) Narcotic Antagonist Treatment: Clinical Experience with Naltrexone. International Journal of the Addictions 13:6, pages 961-973.
Read now
Read now
Frederic Suffet, Daniel C. Remine, Elizabeth Taleporos & Richard Brotman. (1978) Naltrexone and Conventionality. The American Journal of Drug and Alcohol Abuse 5:2, pages 221-233.
Read now
Read now
Articles from other publishers (50)
Piyusha P. Pagare, Rachael Flammia & Yan Zhang. (2023) IUPHAR review: Recent Progress in the Development of Mu Opioid Receptor Modulators to Treat Opioid Use Disorders. Pharmacological Research, pages 107023.
Crossref
Crossref
Hongguang Ma, Piyusha P. Pagare, Mengchu Li, Logan T. Neel, Rolando E. Mendez, James C. Gillespie, David L. Stevens, William L. Dewey, Dana E. Selley & Yan Zhang. (2022) Structural Alterations of the “Address” Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity. Journal of Medicinal Chemistry 66:1, pages 577-595.
Crossref
Crossref
Piyusha P. Pagare, Samuel Obeng, Boshi Huang, Madison M. Marcus, Katherine L. Nicholson, Andrew E. Townsend, Matthew L. Banks & Yan Zhang. (2022) Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment. ACS Pharmacology & Translational Science 5:11, pages 1197-1209.
Crossref
Crossref
Piyusha P. Pagare, Mengchu Li, Yi Zheng, Abhishek S. Kulkarni, Samuel Obeng, Boshi Huang, Christian Ruiz, James C. Gillespie, Rolando E. Mendez, David L. Stevens, Justin L. Poklis, Matthew S. Halquist, William L. Dewey, Dana E. Selley & Yan Zhang. (2022) Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists. Journal of Medicinal Chemistry 65:6, pages 5095-5112.
Crossref
Crossref
Amber N. Edinoff, Catherine A. Nix, Claudia V. Orellana, Samantha M. StPierre, Erin A. Crane, Blaine T. Bulloch, Elyse M. Cornett, Rachel L. Kozinn, Adam M. Kaye, Kevin S. Murnane & Alan D. Kaye. (2021) Naltrexone Implant for Opioid Use Disorder. Neurology International 14:1, pages 49-61.
Crossref
Crossref
Hongguang Ma, Samuel Obeng, Huiqun Wang, Yi Zheng, Mengchu Li, Abdulmajeed M. Jali, David L. Stevens, William L. Dewey, Dana E. Selley & Yan Zhang. (2019) Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators. Journal of Medicinal Chemistry 62:24, pages 11399-11415.
Crossref
Crossref
Rebecca C. Price, Nicolas V. Christou, Steven B. Backman, Laura Stone & Petra Schweinhardt. (2016) Opioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals. Psychopharmacology 233:23-24, pages 3869-3879.
Crossref
Crossref
Yunyun Yuan, Saheem A. Zaidi, Orgil Elbegdorj, Lindsey C. K. Aschenbach, Guo Li, David L. Stevens, Krista L. Scoggins, William L. Dewey, Dana E. Selley & Yan Zhang. (2013) Design, Synthesis, and Biological Evaluation of 14-Heteroaromatic-Substituted Naltrexone Derivatives: Pharmacological Profile Switch from Mu Opioid Receptor Selectivity to Mu/Kappa Opioid Receptor Dual Selectivity. Journal of Medicinal Chemistry 56:22, pages 9156-9169.
Crossref
Crossref
Charles P. O'Brien. 2012. Translational Neuroscience. Translational Neuroscience
107
117
.
F Moeller. 2012. Pharmacogenomics of Alcohol and Drugs of Abuse. Pharmacogenomics of Alcohol and Drugs of Abuse
195
210
.
Silvia Minozzi, Laura Amato, Simona Vecchi, Marina Davoli, Ursula Kirchmayer & Annette Verster. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Kimberly L. KjomeF. Gerard Moeller. (2011) Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence. Substance Abuse: Research and Treatment 5, pages SART.S5452.
Crossref
Crossref
Robert P. Schwartz, Shannon Gwin Mitchell, Michael S. Gordon & Timothy W. Kinlock. 2011. Handbook of Evidence-Based Substance Abuse Treatment in Criminal Justice Settings. Handbook of Evidence-Based Substance Abuse Treatment in Criminal Justice Settings
259
277
.
Donna M. Coviello, James W. Cornish, Kevin G. Lynch, Arthur I. Alterman & Charles P. O’Brien. (2010) A Randomized Trial of Oral Naltrexone for Treating Opioid‐Dependent Offenders. The American Journal on Addictions 19:5, pages 422-432.
Crossref
Crossref
John A. Renner & Joji Suzuki. 2011. Addiction Medicine. Addiction Medicine
463
493
.
Amy Gibson & Alison Ritter. 2009. Pharmacotherapies for the Treatment of Opioid Dependence. Pharmacotherapies for the Treatment of Opioid Dependence
252
281
.
Margaret Haney & Roger Spealman. (2008) Controversies in translational research: drug self-administration. Psychopharmacology 199:3, pages 403-419.
Crossref
Crossref
Allan J. Goodman, Bertrand Le Bourdonnec & Roland E. Dolle. (2007) Mu Opioid Receptor Antagonists: Recent Developments. ChemMedChem 2:11, pages 1552-1570.
Crossref
Crossref
Evgeny M. Krupitsky, Edwin E. Zvartau, Dimitry V. Masalov, Marina V. Tsoy, Andrey M. Burakov, Valentina Y. Egorova, Tatyana Y. Didenko, Tatyana N. Romanova, Eva B. Ivanova, Anton Y. Bespalov, Elena V. Verbitskaya, Nikolai G. Neznanov, Alexandr Y. Grinenko, Charles P. O'Brien & George E. Woody. (2006) Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. Journal of Substance Abuse Treatment 31:4, pages 319-328.
Crossref
Crossref
Charles O'Brien & James W. Cornish. (2006) Naltrexone for probationers and parolees. Journal of Substance Abuse Treatment 31:2, pages 107-111.
Crossref
Crossref
Silvia Minozzi, Laura Amato, Simona Vecchi, Marina Davoli, Ursula Kirchmayer & Annette Verster. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Charles P. O'Brien & Eliot L. Gardner. (2005) Critical assessment of how to study addiction and its treatment: Human and non-human animal models. Pharmacology & Therapeutics 108:1, pages 18-58.
Crossref
Crossref
Frank J. Symons, Andrea Thompson & Michael C. Rodriguez. (2004) Self-injurious behavior and the efficacy of naltrexone treatment: A quantitative synthesis. Mental Retardation and Developmental Disabilities Research Reviews 10:3, pages 193-200.
Crossref
Crossref
Evgeny M Krupitsky, Edwin E Zvartau, Dimitry V Masalov, Marina V Tsoi, Andrey M Burakov, Valentina Y Egorova, Tatyana Y Didenko, Tatyana N Romanova, Eva B Ivanova, Anton Y Bespalov, Elena V Verbitskaya, Nikolai G Neznanov, Alexandr Y Grinenko, Charles P O'Brien & George E Woody. (2004) Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment 26:4, pages 285-294.
Crossref
Crossref
Travis Thompson, Jennifer Zarcone & Frank Symons. 2004. The International Handbook of Applied Research in Intellectual Disabilities. The International Handbook of Applied Research in Intellectual Disabilities
549
580
.
U Kirchmayer, M Davoli & A Verster. 1996. The Cochrane Database of Systematic Reviews. The Cochrane Database of Systematic Reviews.
Ursula Kirchmayer, Marina Davoli, Annette D. Verster, Laura Amato, Arica Ferri & Carlo A. Perucci. (2002) A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 97:10, pages 1241-1249.
Crossref
Crossref
Agustín Madoz-Gúrpide, Enriqueta Ochoa & Enrique Baca-García. (2002) Revisión de la efectividad de los programas de mantenimiento con naltrexona: parámetros de evaluación, perfiles de indicación y factores asociados. Medicina Clínica 119:9, pages 351-355.
Crossref
Crossref
Margaret R. Rukstalis, Michael F. Stromberg, Charles P. O'Brien & Joseph R. Volpicelli. (2006) 6‐β‐Naltrexol Reduces Alcohol Consumption in Rats. Alcoholism: Clinical and Experimental Research 24:10, pages 1593-1596.
Crossref
Crossref
Eli Lawental. (2000) Ultra Rapid Opiate Detoxification as Compared to 30-Day Inpatient Detoxification Program—A Retrospective Follow-up Study. Journal of Substance Abuse 11:2, pages 173-181.
Crossref
Crossref
THAMIZAN K TUCKER & ALISON J. RITTER. (2009) Naltrexone in the treatment of heroin dependence: a literature review. Drug and Alcohol Review 19:1, pages 73-82.
Crossref
Crossref
Leanne D. Mitchem, C.K. Kruschel, E. Dallman, Katie A. Anders, Megan Czapiga, John J. Panos & Rhea E. Steinpreis. (1999) The Effects of the Naltrexone Implant on Rodent Social Interactions and Cocaine-Induced Conditioned Place Preference. Pharmacology Biochemistry and Behavior 62:1, pages 97-102.
Crossref
Crossref
James W. Cornish, David Metzger, George E. Woody, David Wilson, A.Thomas McLellan, Barry Vandergrift & Charles P. O'Brien. (1997) Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment 14:6, pages 529-534.
Crossref
Crossref
Jonathan Rabinowitz, Hagit Cohen, Ricardo Tarrasch & Moshe Kotler. (1997) Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug and Alcohol Dependence 47:2, pages 77-86.
Crossref
Crossref
M. J. Kreek. 1996. Pharmacological Aspects of Drug Dependence. Pharmacological Aspects of Drug Dependence
563
598
.
Emi N. Shufman, Shai Porat, Eliezer Witztum, Dan Gandacu, Rachel Bar-Hamburger & Yigal Ginath. (1994) The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biological Psychiatry 35:12, pages 935-945.
Crossref
Crossref
Olivier Rascol, Nelly Fabre, Olivier Blin, Janet Poulik, Umberto Sabatini, Jean‐Michel Senard, Michèle Ané, Jean‐Louis Montastruc & André Rascol. (2004) Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Movement Disorders 9:4, pages 437-440.
Crossref
Crossref
James W. CornishM.D.M.D., David HensonM.D.M.D., Sanford LevineM.D.M.D., Joseph VolpicelliM.D., Ph.DM.D., Ph.D, Charles E. InturrisiPh.D.Ph.D., Byron C. YoburnPh.D.Ph.D. & Charles P. O'BrienM.D., Ph.DM.D., Ph.D. (2010) Naltrexone Maintenance. The American Journal on Addictions 2:1, pages 34-38.
Crossref
Crossref
L.-A. Pini, C. Ferretti, T. Trenti, A. Ferrari & E. Sternieri. (1991) Effects of Long-Term Treatment with Naltrexone on Hepatic Enzyme Activity. Drug Metabolism and Drug Interactions 9:2.
Crossref
Crossref
Charles P. O’Brien & George E. Woody. 1986. Research Advances in Alcohol and Drug Problems. Research Advances in Alcohol and Drug Problems
245
260
.
Nancy K. Mello & Jack H. Mendelson. (1985) Behavioral pharmacology of buprenorphine. Drug and Alcohol Dependence 14:3-4, pages 283-303.
Crossref
Crossref
George E Woody, Charles P O'Brien & A Thomas McLellan. (1984) Treatments for Opiate Dependence. Psychiatric Annals 14:4, pages 257-263.
Crossref
Crossref
Harold M. Ginzburg & Robert A. Markowitz. 1984. Social and Medical Aspects of Drug Abuse. Social and Medical Aspects of Drug Abuse
157
167
.
Robert A. Greenstein, Bradley D. Evans, A.Thomas Mclellan & Charles P. O'Brien. (1983) Predictors of favorable outcome following naltrexone treatment. Drug and Alcohol Dependence 12:2, pages 173-180.
Crossref
Crossref
Barbara A. Judson, Thomas M. Carney & Avram Goldstein. (1981) Naltrexone treatment of heroin addiction: Efficacy and safety in a double-blind dosage comparison. Drug and Alcohol Dependence 7:4, pages 325-346.
Crossref
Crossref
R. A. Greenstein, J. Grabowski, C. P. O’Brien, Melody Long, G. Woody & S. Livingston. 1981. Drug Dependence and Alcoholism. Drug Dependence and Alcoholism
1043
1049
.
Charles P. O'Brien, Robert Greenstein, Joseph Ternes & George E. Woody. (1978) CLINICAL PHARMACOLOGY OF NARCOTIC ANTAGONISTS. Annals of the New York Academy of Sciences 311:1 Recent Develo, pages 232-240.
Crossref
Crossref
Anthony K. Killian, Kathryn Bonese & Charles R. Schuster. (1978) The effects of naloxone on behavior maintained by cocaine and heroin injections in the rhesus monkey. Drug and Alcohol Dependence 3:4, pages 243-251.
Crossref
Crossref
M.O. MAYKUT. 1978. Neuro-Psychopharmacology. Neuro-Psychopharmacology
245
258
.
M.O. Maykut. (1977) Pharmacotherapy of narcotic dependence. Progress in Neuro-Psychopharmacology 1:1-2, pages 31-49.
Crossref
Crossref